Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors
Steffen Weikert(St. Hedwig-Krankenhaus), Ulrich Keilholz(German Cancer Research Center), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin), Manfred Johannsen(Charité - Universitätsmedizin Berlin), Lisa Weinkauf(Charité - Universitätsmedizin Berlin), Viktor Grünwald(Deutsche Schmerzgesellschaft), Kurt Miller(Charité - Universitätsmedizin Berlin), K. Zimmermann(Helios Klinikum Emil von Behring), Jörg Westermann(Palmetto Hematology Oncology), Anne Flörcken(Humboldt-Universität zu Berlin), Jonas Busch(Charité - Universitätsmedizin Berlin)
Cited by 18
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
|The Lancet|2008|644
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|621